Savara Inc. SVRA
4.82 USD -0.17 (-3.51%)
Nov 12, 2026, 2:43 PM EST
4.67 Day range 5.03
4.03 52-week range 7.01
- YTD
- -20.15%
- 1 year
- +16.87%
- Market cap
- 1.06B
- EPS (ttm)
- -0.60
- Shares out
- 220.62M
- Forward P/E
- -14.32
- YTD return
- -20.15%
- 1-year return
- +16.87%
- Volume
- 2.90M
- Avg volume
- 2.23M
- Open
- 5.03
- Previous close
- 4.99
- Day's range
- 4.67 – 5.03
- 52-week range
- 4.03 – 7.01
- Beta
- 0.30
- Analysts
- Strong Buy
- Price target
- 11.06 (+129.6%)
- Earnings date
- Mar 12, 2027
5D +0.57 (+12.45%)
Key statistics
- Enterprise value
- 1.23B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.50
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -73.67M
- Total cash
- 131.31M
- Total debt
- 31.57M
- Return on equity
- -151.05%
- Short % of float
- 18.35%
- 50-day average
- 4.97
- 200-day average
- 5.35
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 11.06 +129.6% upside
Now 4.82
- Target (low)
- 9.00
- Target (mean)
- 11.06
- Target (high)
- 16.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 12, 2027
Expected Mar 12, 2027. Consensus EPS estimate -0.1525.
Financials — quick view
SVRA Revenue — quarterly 0
SVRA Net income — quarterly -42.99M
SVRA EPS — quarterly -0.17
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 12, 2027 | Dec 30, 2026 | -0.17 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.17556 | -0.17 | +0.01 | +3.17% |
| Aug 11, 2026 | Jun 30, 2026 | -0.14125 | -0.16 | -0.02 | -13.27% |
| May 12, 2026 | Mar 31, 2026 | -0.14 | -0.15 | -0.01 | -7.14% |
| Mar 13, 2026 | Dec 31, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
| Nov 12, 2025 | Sep 30, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | JP Morgan | init | — | Overweight |
| Dec 23, 2025 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 18, 2025 | Wells Fargo | main | Overweight | Overweight |
| Nov 14, 2025 | Oppenheimer | main | Outperform | Outperform |
| Nov 13, 2025 | Citizens | main | Market Outperform | Market Outperform |
| Oct 23, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- savarapharma.com
News
HC Wainwright & Co. Assumes Savara at Buy, Announces Price Target of $10 - Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients
JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12 
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday 
Savara Announces Acceptance Of Oral Presentation, Two Poster Presentations From Phase 3 IMPALA-2 Clinical Studies At ERS Congress 
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041 
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate 
Savara Chief Financial And Administrative Officer Dave Lowrance Stepping Down, Effective July 15; COO Robert Lutz To Assume Additional Role Of CFO 
Savara Presents New Biomarker Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP, At ATS 2026 International Conference - Savara Presents New Exercise Capacity Data From Double-Blind Period Of IMPALA-2 Phase 3 Clinical Trial Evaluating Molgramostim For Treatment Of aPAP At ATS 2026 International Conference
Your note
Sign in to keep a note on SVRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELAM NEVAN C | Director | Stock Award(Grant) | Dec 8, 2025 | 106,887 |
| ERICKSON ANNE | Officer | Stock Award(Grant) | Dec 11, 2024 | 434,672 |
| HAWKINS RICHARD JAMES | Director | Stock Award(Grant) | Dec 8, 2025 | 161,326 |
| LOWRANCE DAVID L. CPA | Chief Financial Officer | Sale | Jun 21, 2026 | 536,032 |
| LUTZ ROBERT MATTHEW | Chief Operating Officer | Stock Award(Grant) | Jul 14, 2026 | 328,977 |
| MCCRACKEN JOSEPH S | Director | Conversion of Exercise of derivative security | Feb 12, 2026 | 302,644 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 11.09% | 24,471,264 | 122.11M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.98% | 17,600,621 | 87.83M | Jun 29, 2026 |
| Venrock Adviser, LLC | 6.68% | 14,745,943 | 73.58M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 6.15% | 13,569,000 | 67.71M | Jun 29, 2026 |
| Blackrock Inc. | 5.66% | 12,494,498 | 62.35M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.60% | 12,362,205 | 61.69M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.79% | 6,164,961 | 30.76M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.80% | 3,969,421 | 19.81M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.44% | 3,183,757 | 15.89M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.76% | 1,677,986 | 8.37M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.71% | 1,555,905 | 7.76M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.64% | 1,421,946 | 7.10M | Sep 29, 2026 |